1. MD Anderson establishes new $50M+ biotech fund to choose next promising cancer therapies — Will the FDA panel meeting on COVID vaccines be the most watched FDA meeting ever? — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Abbott Laboratories reports Q4 results

Discussion in 'Abbott' started by anonymous, Jan 23, 2019 at 1:32 PM.

  1. anonymous

    anonymous Guest

    Worldwide sales increased 2.3% to of $7.77 billion. The results were benefited by the higher sales from Medical Devices and Diagnostics businesses.

    Sales from Medical Devices grew 6.7% year-over-year. In Electrophysiology, the 16.7% growth was led by strong performance in cardiac mapping and ablation catheters. The 12.4% growth in Structural Heart was driven by several product areas across Abbott’s broad portfolio. In Diabetes Care, sales jumped 28.3%, led by rapid market uptake of FreeStyle Libre, which removes the need for routine fingersticks for people with diabetes.

    Source: https://news.alphastreet.com/abbott-laboratories-q4-2018-earnings-results-abt-stock/

  2. anonymous

    anonymous Guest

    Impressive data to say the least. Abbott may finally have taken the corner and will be on the move in 2019!
  3. anonymous

    anonymous Guest

    Looking forward to earnings transcripts! St. Jude and Libre certainly performed! Thankful stockholder Dump the Junk Miles!